Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald

Equities research analysts at Cantor Fitzgerald started coverage on shares of Atyr PHARMA (NASDAQ:ATYR) in a research report issued to clients and investors on Monday,Briefing.com Automated Import reports. The firm set an “overweight” rating on the stock.

Other equities analysts have also recently issued reports about the company. Wells Fargo & Company assumed coverage on Atyr PHARMA in a research note on Friday, October 4th. They issued an “overweight” rating and a $17.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Tuesday, December 10th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $19.25.

Atyr PHARMA Price Performance

NASDAQ:ATYR opened at $4.12 on Monday. The company has a market cap of $345.84 million, a P/E ratio of -4.38 and a beta of 1.07. The stock has a 50 day moving average price of $3.30. The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.02. Atyr PHARMA has a 1-year low of $1.39 and a 1-year high of $4.12.

Atyr PHARMA (NASDAQ:ATYR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.01). As a group, sell-side analysts anticipate that Atyr PHARMA will post -0.89 EPS for the current year.

Institutional Trading of Atyr PHARMA

An institutional investor recently raised its position in Atyr PHARMA stock. JPMorgan Chase & Co. lifted its position in shares of Atyr PHARMA INC (NASDAQ:ATYR) by 52.0% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 31,440 shares of the company’s stock after purchasing an additional 10,754 shares during the quarter. JPMorgan Chase & Co.’s holdings in Atyr PHARMA were worth $55,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 61.72% of the company’s stock.

Atyr PHARMA Company Profile

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.